Evonik announces the opening of its largest center for medical device applications in Shanghai, serving the entire Asian market. This cutting-edge facility specializes in the research, development, and processing of semi-finished components for bioresorbable medical devices, aiming to support customers in overcoming challenges related to the innovation of high-quality medical devices.
The medical device market in Asia is expecting strong growth in the coming years, including double-digit growth in China, as the demand for advanced medical care and high-value medical components continues to rise. This trend is further bolstered by governmental policies to promote the development of innovative medical devices.
“Our next-generation biomaterials are enabling our customers to innovate new medical technologies that create life beyond limits. The latest addition to our global technical service network can help more customers across Asia in reducing complexity, accelerating time to market, and improving medical device performance,” says Yann d’Hervé, head of Evonik Health Care.
The Evonik Shanghai Medical Device Center offers comprehensive one-stop solutions that range from concept development, material selection and customization, prototyping and processing, analytical services, quality and regulatory documentation, to manufacturing semi-finished products and components in an ISO class 7 cleanroom environment. By utilizing advanced processing technologies, the center converts Evonik’s wide range of standard and customized biomaterials into various types of semi-finished components. These components are designed with specific properties, including bioresorbability, low-friction, antithrombotic and antibacterial characteristics. Medical device manufacturers can then further process them to meet specific requirements for diverse applications in orthopedics, sports medicine, general surgery, cardiovascular care, neurosurgery, urology, aesthetics, ophthalmology, and dental care.
“The innovation of high-end medical devices plays a key role in the government’s Healthy China 2030 initiative. Manufacturers are increasingly pursuing competitive raw materials and service solutions to differentiate themselves in the world’s second-largest medical device market,” said Fuliang Xia, President of Evonik Greater China. “Our new center is strategically aligned with these urgent market demands and contributes to the acceleration of industrial upgrading.”
Evonik is a global innovation hub for next-generation biomaterials, encompassing bioresorbable polymers, surface modification technology, biosynthetic cellulose, and non-animal-derived recombinant collagen platforms. These materials provide unique safety and performance advantages, making them exceptionally suitable for high-end medical consumables. Moreover, the company partners with customers to bring their ideas from concept to market, opening up new possibilities for patient-specific treatments.
